New Claims Editing Rules To Be Implemented in December 2026
Blue Cross Blue Shield of Texas is implementing new claims editing rules effective December 1, 2026, that will enforce specific unit limits on five specialty injectable drugs (Denosumab, Aflibercept, Ranibizumab, Pasireotide, and Ranibizumab-eqrn) and require proper application of drug wastage modifiers on single-use vial claims. Claims that fail these edits will receive ineligible reason codes beginning with 'G.' Billing teams must update systems and provider education to comply with these new frequency and unit limitations.